Main Content

Research

We are a team of scientists specialized in the development of broad-spectrum antiviral drugs. Our research focuses on the identification of compounds that inhibit the initiation of translation by the cellular RNA helicase eIF4A. We investigate natural compounds such as rocaglates, pateamines, and synthetic derivatives of these compounds, which are capable of clamping RNA substrates onto the surface of eIF4A. Through this mechanism, the unwinding of stable RNA structures can be blocked, thereby preventing virus replication in our cells (so-called host-targeting antivirals).

Our research results have the potential to make an important contribution to the fight against pandemics. Measures that lead to better preparedness for future outbreak situations with novel viruses are of outstanding importance. Therefore, we work closely with other national and international researchers in a multidisciplinary environment to translate our results into clinical applications.

So far, we have been able to demonstrate the high efficacy of rocaglates, such as silvestrol, with good tolerability for non-infected healthy cells, in a wide range of human pathogenic RNA viruses. These include not only coronaviruses but also extremely dangerous viruses such as the Ebola virus or viruses that cause Lassa fever. Furthermore, we are part of the LOEWE research center DRUID (drug development against neglected tropical diseases) where we expand our concept of eIF4A inhibition to other pathogens like Schistosoma mansoni or Plasmodium falciparum.

Our homepage provides you with an overview of our current research projects and publications. We invite you to get to know the members of the Grünweller research group and to contact us if you have any questions or are interested in joining our team for an internship or a master thesis. We are always looking for enthusiastic and motivated students.